Company Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.
Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia.
The company was founded in 2018 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Dr. Stephen Uden M.B, M.D. |
Contact Details
Address: 234 Church Street, Suite 1020 New Haven, Connecticut 06510 United States | |
| Phone | 203- 859-3820 |
| Website | rallybio.com |
Stock Details
| Ticker Symbol | RLYB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.00 |
| CIK Code | 0001739410 |
| CUSIP Number | 75120L100 |
| ISIN Number | US75120L1008 |
| Employer ID | 85-1083789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Martin W. MacKay Ph.D. | Co-Founder and Executive Chairman |
| Dr. Stephen Uden M.B, M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Jonathan I. Lieber M.B.A. | Chief Financial Officer and Treasurer |
| Ami Bavishi | Head of Investor Relations and Corporate Communications |
| Dr. Steven W. Ryder F.A.C.P, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2024 | D | Notice of Exempt Offering of Securities |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 10, 2024 | 8-K | Current Report |
| Mar 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 9, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | 8-K | Current Report |